Peter Attia· MD
Well, we know it bound to FKBP rapamycin. But you didn't know that that exclusively bound to it, did you? We didn't. But we knew that it could be competed by FK506 based on some competition -type experiments.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Well, we know it bound to FKBP rapamycin. But you didn't know that that exclusively bound to it, did you? We didn't. But we knew that it could be competed by FK506 based on some competition -type experiments.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.